Merck considering takeover of Cubist Pharmaceuticals

posted by Phill Allen

December, 08th, 2014

Company News

American drug giant Merck is reportedly eying up a possible acquisition of the biopharmaceuticals company Cubist Pharmaceuticals.
Merck considering takeover of Cubist Pharmaceuticals
The deal, according to the New York Times, could be announced as early as next week. Merck could pay around $100 a share in a move which would value the US antibiotics maker in the range of $7.5 billion.
Cubist, which makes drugs to treat dangerous bacteria and superbugs in the developing world, has seen its share value nearly double over the last two years.
Should the deal go through it would mark the latest in a long line of multibillion-dollar pharmaceutical mergers and acquisitions.
Merck, one of America’s largest makers of vaccines, prescription products and oncology treatments, has a market value in excess of $174 billion.

Related reading:

TAGS: Cubist Pharmaceuticals, Merck, Pharmaceutical company,

SHARE:

Author

Phill Allen

Managing Director

Phill is an innovative thinker particularly in fluid management. His expertise lies in ensuring the seamless flow of pharmaceutical liquid logistics, whether it's optimising current processes or pioneering new approaches.

ALLpaQ Achieves EcoVadis Gold: A Milestone in Our Ongoing Sustainability Journey
Company News

ALLpaQ Achieves EcoVadis Gold: A Milestone in Our Ongoing Sustainability Journey

We’re thrilled to announce that ALLpaQ has been awarded EcoVadis Gold – a globally recognised benchmark that places us among […]

Jun 12th, 2025

Health & Safety at ALLpaQ: Meet the Team That Keeps Us Safe
Careers Company News Containers

Health & Safety at ALLpaQ: Meet the Team That Keeps Us Safe

Apr 28th, 2025